07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Aptose Biosciences, Oregon Health & Science University, LLS cancer news

Aptose (formerly Lorus Therapeutics Inc. ) joined the Beat AML cancer research initiative to create a profile of the possible genetic drivers of acute myelogenous leukemia (AML). Oregon's Knight Cancer Institute and Aptose will profile...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

LOR-253: Phase Ib start

In mid-September, Lorus will begin an open-label, U.S. Phase Ib trial to evaluate LOR-253 in about 45-60 patients with relapsed or refractory hematologic malignancies, including acute myelogenous leukemia (AML), high-risk myelodysplastic syndrome (MDS), lymphoma and...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

3Q14 Financial Markets Preview: Discerning optimism

Investors and bankers are cautiously optimistic that the correction that began in late 1Q14 will provide a floor for a biotech recovery that should continue through the third quarter, with investors being more selective on...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Financial News

Lorus completes warrant exercise

Lorus Therapeutics Inc. (TSX:LOR; Pink:LRUSF), Toronto, Ontario   Business: Cancer, Gene/Cell therapy   Date completed: 6/10/14   Type: Warrant exercise   Raised: C$384,000 ($351,552)   Shares: 1.2 million   Price: C$0.32   Shares after offering:...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Financial News

Lorus completes warrant exercise

Lorus Therapeutics Inc. (TSX:LOR; Pink:LRUSF), Toronto, Ontario   Business: Cancer, Gene/Cell therapy   Date completed: 6/10/14   Type: Warrant exercise   Raised: C$8.3 million ($7.6 million)   Shares: 18.5 million   Price: C$0.45   Shares...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Financial News

Lorus financial update

Lorus raised C$3.3 million ($2.9 million) through the sale of 6.5 million shares at C$0.50 to cover the overallotment from its April 10 follow-on, bringing the total raised to C$28.3 million ($25.7 million). The company,...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Financial News

Lorus completes follow-on

Lorus Therapeutics Inc. (TSX:LOR; Pink:LRUSF), Toronto, Ontario   Business: Cancer, Gene/Cell therapy   Date completed: 4/10/14   Type: Follow-on   Raised: C$25 million ($22.8 million)   Shares: 50 million   Price: C$0.50   Shares after...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Financial News

Lorus proposes follow-on

Lorus Therapeutics Inc. (TSX:LOR; Pink:LRUSF), Toronto, Ontario   Business: Cancer, Gene/Cell therapy   Date announced: 3/26/14   Type: Follow-on   To be raised: C$25 million ($22.2 million)   Shares: 50 million   Price: C$0.50  ...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Lorus management update

Lorus Therapeutics Inc. (TSX:LOR; Pink:LRUSF), Toronto, Ontario   Business: Cancer, Gene/Cell therapy   Departed: Aiping Young as president and COO  ...